Ribo Life Science Seeks European Phase I Clinical Trial Approval

Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals have announced the submission of a Clinical Trial Application (CTA) to European authorities for a Phase I study of their RNAi therapeutic, RBD3133. The application seeks approval to initiate human trials in Europe.

The investigational drug targets the inhibition of the INHBE protein. The Phase I study is designed to assess the safety and tolerability of RBD3133 in adult participants. Specific trial sites and timelines have not yet been disclosed.

Ribo Life Science, traded on the Hong Kong Stock Exchange (06938.HK), specializes in the development of RNA-based therapeutics. The company aims to address unmet medical needs across various diseases.

The inhibition of INHBE is being explored as a potential therapeutic strategy for certain conditions. This submission marks a significant step in advancing RBD3133 towards clinical evaluation.